EVGN: 分析师目标 $4 — AI 分析 (4月 2026)
Evogene Ltd. is a computational biology company focused on product discovery and development in life-science based industries, including human health and agriculture. The company leverages its computational predictive biology (CPB) platform to enhance plant performance and develop microbiome-based therapeutics.
公司概况
概要：
EVGN是做什么的？
EVGN的投资论点是什么？
EVGN在哪个行业运营？
EVGN有哪些增长机遇？
- Human Health Therapeutics: Evogene's development of microbiome-based therapeutics for immuno-oncology and gastrointestinal disorders represents a significant growth opportunity. The global market for microbiome therapeutics is projected to reach billions of dollars in the coming years. Successful clinical trials and FDA approval could drive substantial revenue growth for Evogene. Timeline: Ongoing clinical trials with potential for data readouts in the next 12-24 months.
- Agricultural Seed Traits: The Agriculture segment offers growth potential through the development of improved seed traits that enhance plant performance. The global market for seed traits is substantial, driven by increasing demand for higher crop yields and improved resistance to pests and diseases. Evogene's CPB platform can accelerate the discovery and development of novel seed traits. Timeline: Ongoing research and development with potential for commercialization of new seed traits in the next 3-5 years.
- Ag-Biological Products: Development of ag-biological products presents another growth avenue. The market for ag-biologicals is expanding as farmers seek sustainable alternatives to traditional pesticides and fertilizers. Evogene's expertise in computational biology can facilitate the discovery of novel ag-biological solutions. Timeline: Ongoing research and development with potential for commercialization of new ag-biological products in the next 2-4 years.
- Industrial Applications: The Industrial Applications segment, focused on improved castor bean seeds, offers a niche growth opportunity. Castor bean oil is used in various industrial applications, and Evogene's improved seeds can increase yields and reduce production costs. Timeline: Ongoing development and commercialization efforts with potential for increased market penetration in the next 1-3 years.
- Medical Cannabis Products: Evogene's involvement in medical cannabis provides exposure to a rapidly growing market. The global medical cannabis market is projected to experience significant growth in the coming years, driven by increasing legalization and acceptance. Evogene can leverage its expertise in plant biology to develop high-quality medical cannabis products. Timeline: Ongoing operations with potential for expansion and increased market share in the next 1-2 years.
- Market Cap of $0.01 billion indicates a micro-cap stock with potential for high growth but also higher risk.
- P/E ratio of -2.71 reflects current losses but also potential for future earnings growth.
- Gross Margin of 44.0% demonstrates the company's ability to generate revenue exceeding its cost of goods sold.
- Beta of 1.18 suggests the stock is slightly more volatile than the market.
- No dividend yield indicates that the company is reinvesting earnings for growth.
EVGN提供哪些产品和服务？
- Develop seed traits to enhance plant performance.
- Create ag-chemical products for improved crop protection.
- Produce ag-biological products as sustainable agricultural solutions.
- Discover and develop human microbiome-based therapeutics.
- Target immuno-oncology, gastrointestinal disorders, and antimicrobial resistance.
- Develop and commercialize improved castor bean seeds for industrial uses.
- Provide medical cannabis products.
EVGN如何赚钱？
- Develops and licenses its computational predictive biology (CPB) platform.
- Generates revenue through the sale of agricultural products, including seed traits and ag-biologicals.
- Out-licenses or co-develops its human health therapeutics with pharmaceutical partners.
- Sells medical cannabis products in regulated markets.
- Agricultural companies seeking improved seed traits and crop protection solutions.
- Pharmaceutical companies interested in microbiome-based therapeutics.
- Industrial companies requiring castor bean oil for various applications.
- Patients seeking medical cannabis products in regulated markets.
- Proprietary Computational Predictive Biology (CPB) platform accelerates product discovery.
- Diverse portfolio across agriculture, human health, and industrial applications reduces risk.
- Strategic collaborations with leading research institutions and industry partners.
- Intellectual property portfolio protects its innovations.
什么因素可能推动EVGN股价上涨？
- Upcoming: Clinical trial data readouts for microbiome-based therapeutics in the Human Health segment.
- Upcoming: Potential partnerships and licensing agreements for its CPB platform and product candidates.
- Ongoing: Progress in the development and commercialization of improved seed traits and ag-biological products.
- Ongoing: Expansion of its medical cannabis operations in regulated markets.
EVGN的主要风险是什么？
- Potential: Dilution risk due to the need for additional capital to fund operations.
- Potential: Regulatory risks associated with the development and commercialization of its products.
- Ongoing: Competition from larger and more established companies in the biotechnology and agricultural industries.
- Ongoing: Risk of clinical trial failures and product development setbacks.
EVGN的核心优势是什么？
- Proprietary computational predictive biology (CPB) platform.
- Diverse portfolio across multiple life-science industries.
- Strategic collaborations with leading institutions.
- Strong intellectual property portfolio.
EVGN的劣势是什么？
- Limited financial resources and reliance on external funding.
- High R&D costs and long development timelines.
- Dependence on regulatory approvals for product commercialization.
- Negative profit margin.
EVGN有哪些机遇？
- Expanding market for microbiome-based therapeutics.
- Growing demand for sustainable agricultural solutions.
- Increasing legalization of medical cannabis.
- Potential for strategic partnerships and licensing agreements.
EVGN面临哪些威胁？
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and changing regulations.
- Clinical trial failures and product development setbacks.
- Economic downturns and market volatility.
EVGN的竞争对手是谁？
- Aeon Biopharma, Inc. — Focuses on botulinum toxin products. — (AEON)
- Bolt Biotherapeutics, Inc. — Develops immuno-oncology therapies. — (BOLT)
- Cingulate Inc. — Develops ADHD medications. — (CING)
- Cellectar Biosciences Inc. — Develops cancer therapeutics. — (CLRB)
- Cocrystal Pharma, Inc. — Focuses on antiviral drug discovery. — (COCP)
Key Metrics
- Price: $0.82 (-3.28%)
- Market Cap: $8
- Volume: NaN
- MoonshotScore: 44/100
Analyst Price Target
- Analyst Consensus Target: $3.50
- Current Price: $0.82
- Implied Upside: +326.8%
常见问题
What does Evogene Ltd. (EVGN) do?
Evogene Ltd. (EVGN) is a computational biology company that utilizes its proprietary computational predictive biology (CPB) platform to discover and develop products across various life-science industries, including agriculture, human health, and industrial applications. In agriculture, Evogene focuses on enhancing plant performance through seed traits and ag-biological products. In human health, the company develops microbiome-based therapeutics targeting conditions like immuno-oncology and gastrointestinal disorders. Additionally, Evogene is involved in the development of improved castor bean seeds for industrial uses and provides medical cannabis products, showcasing a diversified approach to leveraging its CPB platform.
Is EVGN stock a good buy?
Evaluating whether EVGN stock is a good buy requires careful consideration of its potential and risks. With a market cap of $0.01 billion and a negative P/E ratio, Evogene is a high-risk, high-reward investment. The company's innovative CPB platform and diverse portfolio offer significant growth potential, particularly in the expanding markets for microbiome-based therapeutics and sustainable agriculture. However, investors should be aware of the company's limited financial resources and reliance on external funding, which could lead to dilution. A balanced assessment suggests that EVGN may be suitable for investors with a high-risk tolerance and a long-term investment horizon.
What are the main risks for EVGN?
Investing in Evogene (EVGN) carries several risks that investors may want to research. A primary risk is the potential for dilution, as the company may need to raise additional capital to fund its operations and research and development activities. Regulatory risks are also significant, given the stringent requirements for the development and commercialization of biotechnology and agricultural products. Competition from larger, more established companies poses another challenge. Additionally, the inherent risks associated with clinical trials and product development, including the possibility of failures or setbacks, could negatively impact the company's prospects.
What catalysts could move EVGN stock?
Several catalysts could potentially move EVGN stock. Positive data readouts from clinical trials of its microbiome-based therapeutics in the Human Health segment could significantly boost investor confidence. Successful partnerships and licensing agreements for its CPB platform or product candidates would also be viewed favorably. Progress in the development and commercialization of improved seed traits and ag-biological products in the Agriculture segment could drive revenue growth. Furthermore, expansion of its medical cannabis operations in regulated markets could provide additional upside potential. Investors should closely monitor these developments for potential catalysts.
What is EVGN stock price target?
As of March 3, 2026, there is no readily available analyst consensus price target for EVGN stock, likely due to its micro-cap status and limited analyst coverage. Given the absence of analyst targets, a fair value estimate would require a detailed financial model incorporating Evogene's projected revenue growth, profitability, and discount rate. Investors should conduct their own due diligence and consider the company's growth opportunities, risks, and financial position to determine a reasonable valuation range. The company's innovative CPB platform and diverse portfolio warrant consideration, but caution is advised given its micro-cap status and inherent risks.
Is EVGN a good investment right now?
Use the AI score and analyst targets on this page to evaluate Evogene Ltd. (EVGN). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.
What is the MoonshotScore for EVGN?
The MoonshotScore is a proprietary 0-100 AI rating that evaluates Evogene Ltd. across multiple dimensions including financial health, growth trajectory, and risk factors.
Where can I find EVGN financial statements?
Evogene Ltd. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.